Standard BioTools Inc. (Nasdaq: LAB) achieved stockholder approval for its merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders. Michael Egholm, CEO, expressed gratitude for the support, anticipating increased customer service and shareholder value through the merger. The final vote results will be filed with the SEC. The merger, subject to customary conditions, is set to finalize on January 5, 2024.
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders.
“We are pleased with the outcome of today’s Special Meeting and thank our stockholders for their support for this merger,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “Together with SomaLogic, we will have an expanded platform to better serve our customers and we believe we will be able to deliver significant shareholder value through enhanced scale and a strengthened balance sheet to fuel future growth.”
Standard BioTools will file the final vote results, as certified by the independent inspector of election, on a Form 8-K with the U.S. Securities and Exchange Commission.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The merger is expected to close on January 5, 2024, subject to satisfaction of certain customary closing conditions.
Source: Bio Space